Archit Organosys Limited is an established Indian chemical manufacturer specializing in the production and trading of organic and specialty chemicals. Operating primarily out of Gujarat, the company has recently undergone a strategic restructuring to streamline its operations, focusing on high-growth pharmaceutical intermediates and advanced agricultural machinery. As of **2026**, the company operates as a standalone entity, leveraging bulk procurement synergies and a robust domestic and international distribution network. --- ### **Core Business Verticals & Product Portfolio** The company operates across two primary industrial pillars, serving a diverse range of end-use industries including Food & Beverages, Textiles, Pharmaceuticals, Agrochemicals, and Petroleum Refining. #### **1. Chemicals and Organics (Specialty & Industrial)** This segment remains the company’s primary revenue driver, focusing on chlorinated compounds and essential chemical intermediates. | Product Category | Key Products | Primary Applications | | :--- | :--- | :--- | | **Core Industrial Chemicals** | Ethyl Acetate, Butyl Acetate, Propyl Acetate, Acetaldehyde, Acetic Anhydride | Solvents, chemical synthesis, and industrial processing. | | **Specialty Intermediates** | Monochloroacetic Acid (**MCA**), Sodium Monochloroacetate (**SMCA**), Trichloroacetyl Chloride (**TCAC**) | **Pharmaceuticals** (Ibuprofen, Diclofenac), **Agrochemicals** (2,4 D-Acid), and **Pigments**. | | **Surfactants & Oil Field Chemicals** | Specialized additives and CMC manufacturing | **Oil Drilling**, **Cosmetics**, and **Personal Care** products. | | **New Pharma Vertical** | **Bulk Drugs** (Import & Marketing) | Direct supply to the domestic pharmaceutical industry. | #### **2. Farm Machinery (High-Technology Mechanization)** Archit has diversified into intelligent agricultural solutions to modernize traditional farming practices. * **Flagship Product**: The **Swaraj 8200 Wheel Harvester**, manufactured in a dedicated **23-acre facility**. * **Technological Edge**: Features an **industry-first intelligent system** providing real-time data on live location, acreage harvested, road kilometers traveled, and fuel consumption. * **Compliance**: Machinery is equipped with in-house **TREM-IV compliant engines**, optimized for fuel economy and minimal grain loss. --- ### **Manufacturing Infrastructure & Operational Footprint** The company maintains a centralized manufacturing base in Gujarat, India, ensuring proximity to key chemical clusters and ports. * **Plant 1**: GIDC Industrial Estate, Naroda, Ahmedabad. * **Plant 2**: Village Narmad, Bhavnagar. * **Strategic Expansion**: In **March 2026**, the company executed a **Banakhat** to purchase additional land in **Bhavnagar (Kala Talav)** for **₹10.51 Crore** to facilitate future capacity scaling. * **Corporate Hub**: The registered office was relocated to **Venus Benecia, S.G. Highway, Ahmedabad** in **November 2023** to modernize corporate operations. --- ### **Financial Performance & Shareholder Value** Archit Organosys demonstrated a sharp recovery in profitability during **FY 2024-25**, characterized by significant margin expansion despite moderate top-line growth. #### **Key Financial Indicators** | Metric (₹ in Crore) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **128.69** | **113.19** | **127.78** | | **Profit Before Tax (PBT)** | **7.54** | **1.01** | **13.79** | | **Revenue Growth (YoY)** | **+11.23%** | **-11.41%** | — | | **Dividend per Share** | **₹ 0.50 (5%)** | **Nil** | **₹ 0.50 (5%)** | #### **Geographical Revenue Distribution (FY 2024-25)** * **India**: **₹101.78 Crore** (Primary market with a Pan-India distribution network). * **Rest of World**: **₹19.83 Crore** (Exports to USA, Europe, Latin America, South Africa, and Asia). --- ### **Strategic Growth Drivers & Market Positioning** * **Specialty Chemical Upside**: Targeting the Indian specialty chemicals market, projected to grow at a **CAGR of 11-12%** through **2027**. * **China Plus One Strategy**: Positioning as a reliable alternative to Chinese manufacturers in the global supply chain for chlorinated compounds. * **Pharma-Linked Growth**: Actively diversifying into the pharma line by importing bulk drugs and reducing process cycles through intensive **R&D**. * **Policy Tailwinds**: Leveraging government initiatives including **PLI schemes** and **PCPIRs** (Petroleum, Chemicals and Petrochemicals Investment Regions). --- ### **Corporate Restructuring & Governance** The company has aggressively streamlined its portfolio to focus on core competencies: * **Subsidiary Divestment**: Ceased relationship with **Archit Life Science Limited** as a subsidiary in **June 2024** (retaining a **19%** stake). Retired as a partner from **Novel and Nano Xtreme Solutions LLP** in **March 2024**. * **Debt Management**: Total borrowings reduced to **₹25.66 Crore** (March 2024). Major facilities are secured with **Union Bank of India**. * **Legal Resolution**: Successfully resolved a long-standing derivative dispute with **HDFC Bank** via a **One-Time Settlement (OTS)** of **₹2.50 Crore**, leading to the dismissal of NCLT insolvency proceedings in **March 2024**. * **Leadership**: Appointed **Mr. Ajay P Patel** as **CFO** in **May 2025** to strengthen financial oversight. --- ### **Risk Management & Regulatory Compliance** Archit Organosys employs a formal **Risk Management Policy** to mitigate operational and financial volatility. * **Environmental & Labor Compliance**: Operations adhere to **GPCB** norms. The company transitioned to the **four New Labour Codes** effective **November 21, 2025**, recognizing necessary provisions for defined benefit obligations. * **Market Volatility**: Manages fluctuations in **Chlorine** and **Acetic Acid** prices through bulk volume negotiations. * **Currency & Interest Risk**: Maintains a status as a **net foreign exchange earner** to hedge against USD/Euro volatility. Debt is primarily linked to floating **MCLR** rates. * **Credit Risk**: Exposure is diversified; no single customer exceeds **10%** of total trade receivables, with standard credit terms maintained at **30-60 days**. #### **Maturity Analysis of Defined Benefit Obligation** | Period | Amount (₹ Lacs) | | :--- | :--- | | **Within 1 Year** | **41.81** | | **2 - 10 Years** | **10.79** | | **11 Years and above** | **53.16** |